Q2 2024 · 13F-HR
GENERAL ATLANTIC, L.P.holdings as filed
Filed 2024-08-14 · accession 0000950142-24-002199
$3.18B
Reported value
19
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G98239109 | XP | XP, INC | $521.0M | 16.4% | 29,617,733 | Common | SOLE |
| G29018101 | DLO | DLOCAL | $517.0M | 16.3% | 63,906,695 | Common | SOLE |
| 01644J108 | ALKT | ALKAMI | $489.5M | 15.4% | 17,186,985 | Common | SOLE |
| 01625V104 | ALHC | ALIGNMENT HEALTHCARE | $477.0M | 15.0% | 60,993,323 | Common | SOLE |
| 85225A107 | 8DT | SQUARESPACE | $463.0M | 14.6% | 10,611,073 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS | $141.6M | 4.45% | 7,531,252 | Common | SOLE |
| 29882P106 | EWCZ | EUROPEAN WAX CENTER | $130.2M | 4.09% | 13,110,492 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS | $122.8M | 3.86% | 5,233,989 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS | $87.4M | 2.75% | 9,681,818 | Common | SOLE |
| 09352U108 | BLND | BLEND LABS | $45.2M | 1.42% | 19,132,440 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE | $42.8M | 1.34% | 1,261,684 | Common | SOLE |
| G7709Q104 | RPRX | ROYALTY PHARMA | $39.6M | 1.24% | 1,500,000 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO | $38.5M | 1.21% | 2,958,762 | Common | SOLE |
| M8216R109 | RSKD | RISKIFIED | $34.0M | 1.07% | 5,324,998 | Common | SOLE |
| 00445A100 | — | ACELYRIN | $12.7M | 0.40% | 2,889,668 | Common | SOLE |
| 683712103 | OPEN | OPENDOOR | $11.6M | 0.37% | 6,321,519 | Common | SOLE |
| 21077C305 | 5ZZ0 | WISH | $3.5M | 0.11% | 609,616 | Common | SOLE |
| 39957D201 | GROV | GROVE COLLABORATIVE | $1.7M | 0.05% | 936,020 | Common | SOLE |
| 005329107 | ADAG | ADAGENE | $807,840 | 0.03% | 264,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.